Modifying the risk of atypical antipsychotics in the treatment of juvenile-onset schizophrenia

Bibliography

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington, D.C.; 2000
   Google Scholar
• Heiden W, Hafner H. The epidemiology of onset and course of schizophrenia. Eur Arch Psychiatry Clin Neurosci 2000;250:292-303
   PubMedGoogle Scholar
• Burd L, Kerbeshian J. A North Dakota prevalence study of schizophrenia presenting in childhood. J Am Acad Child Adolesc Psychiatry 1987;26(3):347-50
   PubMedGoogle Scholar
• McKenna K, Gordon CT, Lenane M, Looking for childhood-onset schizophrenia: the first 71 cases screened. J Am Acad Child Adolesc Psychiatry 1994;33:636-44
   PubMed Web of Science ®Google Scholar
• Frazier JA, McClellan J, Findling RL, Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristics. J Am Acad Child Adolesc Psychiatry 2007;46(8):979-88
   PubMed Web of Science ®Google Scholar
• Rabinowitz J, Levine SZ, Hafner H. A population based elaboration of the role of age of onset on the course of schizophrenia. Schizophr Res 2006;88:96-101
   PubMed Web of Science ®Google Scholar
• Realmuto GM, Erickson WD, Yellin AM, Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents. Am J Psychiatry 1984;141(3):440-2
   PubMedGoogle Scholar
• Eggers C, Bunk D. The long-term course of childhood-onset schizophrenia: a 42 year follow up. Schizophr Bull 1997;23(1):105-17
   PubMedGoogle Scholar
• McClellan JM, Werry JS, Ham M. A follow-up study of early onset psychosis: comparison between outcome diagnosis of schizophrenia, mood disorders, and personality disorders. J Autism Dev Disord 1993;23(2):243-62
   PubMedGoogle Scholar
• Meltzer HY, Rabinowitz J, Lee MA, Age at onset and gender of schizophrenia patients in relation to neuroleptic resistance. Am J Psychiatry 1997;154(4):475-82
   PubMedGoogle Scholar
• American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2001;40(7 Suppl):4S-23S
   PubMedGoogle Scholar
• Pool D, Bloom W, Mielke DH, A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Curr Ther Res 1976;19(1):99-104
   PubMedGoogle Scholar
• Naber D, Karow A, Lambert M. Subjective well-being under neuroleptic treatment and its relevance for compliance. Acta Psychiatrica Scandinavica 2005;111(Suppl 427):29-34
   PubMedGoogle Scholar
• Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 1983;40:1113-7
   PubMed Web of Science ®Google Scholar
• Elkis H, Meltzer HY. Refractory schizophrenia. Rev Bras Psiquiatr 2007;29(Suppl 11):S41-7
   Google Scholar
• Kinon BJ, Kane JM, Johns C, Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull 1993;29(2):309-14
   PubMedGoogle Scholar
• Kumra S, Oberstar JV, Sikich L, Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull 2008;34(1):60-71
   PubMedGoogle Scholar
• Kumra S, Frazier JA, Jacobsen LK, Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996;53:1090-7
   PubMed Web of Science ®Google Scholar
• Shaw P, Sporn A, Gogtay N, Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 2006;63:721-9
   PubMed Web of Science ®Google Scholar
• Kumra S, Kranzler H, Gerbino-Rosen G, Clozapine and ‘high-dose’ olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry 2008;63:524-9
   PubMed Web of Science ®Google Scholar
• Hansen TE, Casey DE, Hoffman WF. Neuroleptic intolerance. Schizophr Bull 1997;23(4):567-82
   PubMedGoogle Scholar
• Weiss R, Dziura J, Burgert TS, Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004;350(23):2362-74
   PubMed Web of Science ®Google Scholar
• Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 2008;69(Suppl 4):26-36
   PubMedGoogle Scholar
• Sikich L, Frazier JA, McClellan J, Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: findings from the Treatment of Early-onset Schizophrenia Spectrum Disorders (TEOSS) study. Am J Psychiatry 2008;165:1420-31
   PubMed Web of Science ®Google Scholar
• Correll CU, Carlson HE. Endocrine and metabolic adverse effects of Psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006;45(7):771-91
   PubMedGoogle Scholar
• American Diabetes Association/American Psychiatric Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27(2):596-601
   PubMedGoogle Scholar
• Correll CU, Manu P, Olshanskiy V, Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. J Am Med Assoc 2009;302(16):1765-73
   PubMed Web of Science ®Google Scholar
• Alvarez-Jiminez M, Hetrick SE, Gonzalez-Blanch C, Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 2008;193:101-7
   PubMedGoogle Scholar
• Maloney AE, Bethea TC, Kelsey KS, A pilot of a video game (DDR) to promote physical activity and decrease sedentary screen time. Obesity 2008;16(9):2074-80
   PubMedGoogle Scholar
• Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA 2003;289(14):1805-912
   PubMed Web of Science ®Google Scholar
• Chanoine JP, Hampl S, Jensen C, Effect of Orlistat on weight and body composition in obese adolescents. J Am Med Assoc 2005;293(23):2873-83
   PubMed Web of Science ®Google Scholar
• Desilets AR, Dhakal-Karki S, Dunican KC. Role of metformin for weight management in patients without Type 2 diabetes. Ann Pharmacother 2008;42:817-26
   PubMed Web of Science ®Google Scholar
• Klein DJ, Cottingham EM, Sorter M, A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006;163(12):2072-9
   PubMed Web of Science ®Google Scholar
• Allison DB, Newcomer JW, Dunn AL, Obesity among those with mental health disorders: a National Institute of Mental Health Meeting Report. Am J Prev Med 2009;36(4):341-50
   PubMedGoogle Scholar
• Rockett IRH, Wang S, Lian Y, Stack S. Suicide-associated comorbidity among US males and females: a multiple cause-of-death analysis. Inj Prev 2007;13:311-5
   PubMedGoogle Scholar
• Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia. Arch Gen Psychiatry 2007;64(10):1123-31
   PubMed Web of Science ®Google Scholar
• Findling RL, Robb A, Nyilas M, A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008a;165:1432-41
   PubMed Web of Science ®Google Scholar
• Findling RL, Kline K, McKenna K, Efficacy and safety of quetiapine in adolescents with schizophrenia: a 6-week, double-blind, randomized, placebo-controlled trial. Poster presented at the 55th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, October 28-November 2, Chicago, IL; 2008b
   Google Scholar
• Haas M, Unis AS, Copenhaver M, Efficacy and safety of risperidone in adolescents with schizophrenia. Poster presented at the 160th Annual Meeting of the American Psychological Association, May 19-24, San Diego, CA; 2007
   Google Scholar
• Kryzhanovskaya L, Schulz SC, McDougle C, Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009;48(1):60-70
   PubMedGoogle Scholar
• Haas M, Eerdekens M, Kushner S, Efficacy, safety, and tolerability of two risperidone dosing regimens in adolescent schizophrenia: a double-blind study. Br J Psychiatry 2009;194:158-64
   PubMed Web of Science ®Google Scholar